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Abstract
Aim: Haemorrhagic cystitis (HC) is uncommon and in its severe form potentially life threatening complication of Haematopoi-
etic stem cell transplantation (HSCT) in children. We present our single centre experience in the urological management of this
clinically challenging condition. Patients and Methods: Fourteen patients were diagnosed with BK-Virus HC in our centre. The
mean age at diagnosis was 8.8 years (range, 3.2-18.4 years). The mean number of days post-BMT until onset of HC was 20.8
(range, 1 – 51). While all patients tested urine positive for BKV at the clinical onset of HC, only four patients had viral quantifi-
cation, with viral loads ranging from 97,000 to >1 billion/ml. 8 patients had clinical HC. Ten patients experienced acute GVHD
(grade I: 6 patients, grade II: 3 patients, grade 4: 1 patient). Results: Four patients received medical management for their HC.
Treatments included hyperhydration, MESNA, blood and platelet transfusion, premarin and oxybutynin (Table 6).  Two pa-
tients received both medical and surgical management which included cystoscopy with clot evacuation, bladder irrigation and
supra-pubic catheter insertion. One patient received exclusive surgical management. Seven patients were treated conservative-
ly. Conclusion: There is limited available evidence for other potential therapeutic strategies highlighting the need for more re-
search into the pathophysiology of HSCT-associated HC. Commonly used interventions with possible clinical benefit (e.g.
cidofovir, ciprofloxacin) still require to be evaluated in multi-centre, high-quality studies. Potential future preventative and
therapeutic options, such as modulation of conditioning, immunosuppression and engraftment, new antiviral and an-
ti-inflammatory and less nephrotoxic agents need to be assessed.
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Introduction
A significant number of children undergo haematopoietic
stem cell transplantation (HSCT) for a range of indications
each year. There are various side effects and complications
well understood, many of which occur secondary to immu-
nosuppression. Haemorrhagic cystitis (HC) is characterised
by haemorrhagic inflammation of bladder mucosa which
results in painful micturition associated with haematuria.
The clinical course of HC following HSCT can vary from
from mild and brief (Grade I) to severe, prolonged and
life-threatening (Grade IV).1, 2
Patients who develop HC following HSCT the onset have
either an early or late onset presentation. Early onset occurs
within days of transplantation and is associated with associ-
ated with conditioning regimen (chemotherapy or irradia-
tion). The late-onset form occurs post-engraftment and is
associated with the reactivation of urotropic viruses, princi-
pally BK virus, Adenovirus and CMV.3 In current literature,
numerous conditioning regimens have been used which in-
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clude of the initial use of less toxic conditioning regimens,
uroprotective antitoxic agents (e.g. MESNA)4 or
hyperhydration/forced dieresis regimens.5
A common theory for the onset of HC following HSCT indi-
cates the role of BK virus reactivation during the time of
maximal post-transplant immune suppression in the patho-
genesis of late-onset HC.6 We present our single centre ex-
perience in the urological (medical and surgical) manage-
ment of these patients with this clinically challenging and
difficult clinical diagnosis to manage.
Methods and Materials
The aim of this case series was to investigate the cases of all
children who underwent HSCT and developed BK-virus HC
as a complication, over a 6 year period (2004-2009) at New-
castle General Hospital (NGH). Those who developed
BK-virus positive HC following HSCT (n=14) were identi-
fied. Notes for all eligible children were sourced and data
retrieved on a number of variables: diagnosis necessitating
HSCT, date of HSCT, conditioning regimen, donor (whether
related and nature of relationship or unrelated), HLA match,
Adenovirus and CMV status both pre- and post-HSCT, Graft
versus Host Disease (GvHD) prophylaxis, number of days
post-HSCT of onset of GvHD, grade of maximal GvHD,
treatment of GvHD, number of days post-HSCT of onset of
HC, grade of HC, serial BK viral loads in both urine and se-
rum, surgical treatment of HC, medical treatment of HC,
serial CD45RA+ counts and eventual outcome. Data was
presented on an excel spreadsheet prior to analysis.
Indications for haematopoietic stem cell transplanta-
tion (HSCT)
Fourteen patients in total, ten boys and four girls, with a
mean age of 8.8 years underwent BMT on our unit between
2004 and 2009 and subsequently developed HC. There were
a range of indications. Four had chronic granulomatous dis-
ease and two had complex autoimmune disease.  The re-
maining nine patients presented with one of the following:
combined immune deficiency, familial
haemophagocyticlymphohistocytosis, idiopathic aplastic
anaemia, IPEX like complex autoimmune disease, previous
Wiskott Aldrich syndrome with chronic EBV, severe con-
genital neutropenia (HAX1 gene defect), severe periodic
syndrome, T-cell acute lymphoblastic lymphoma (Table 1).
Conditioning
Ten different conditioning regimens were used in our pa-
tients, almost all of them myeloablative (Table 2). Five re-
ceived busulfan, cyclophosphamide and campath.  One
received each of the following: cyclophosphamide only;
busulfan and cyclophosphamide; campath, fludarabine and
cyclophosphamide; campath, fludarabine and melphalen;
campath, fludarabine and treosulphan; cyclophosphamide,
rituximab and busulfan; melphalan, fludarabine and
campath; rabbit ATG, busulfan and cyclophosphamide;
treosulfan and cyclophosphamide.
TABLE 1: Indications for haematopoietic stem cell transplantation
(HSCT)
Diagnosis Number
of Patients
% ofSeries
Chronic granulomatous disease 4 26.8
Complex autoimmune disease 2 13.3
Combined immune deficiency 1 6.7
Familial
haemophagocyticlymphohistocytosis
1 6.7
Idiopathic aplastic anaemia 1 6.7
IPEX like complex autoimmune dis-
ease
1 6.7
Previous Wiskott Aldrich syndrome
with chronic EBV
1 6.7
Severe congenital neutropenia (HAX1
gene defect)
1 6.7
Severe periodic syndrome 1 6.7
T-cell acute lymphoblastic lymphoma 1 6.7
TABLE 2: Conditioning regimen
Conditioning Regimen Number of
Patients
% ofSeries
Busulfan, cyclophosphamide and
campath
5 33.5
Cyclophosphamide 1 6.7
Busulfan and cyclophosphamide 1 6.7
Campath, fludarabine and cyclophos-
phamide
1 6.7
Campath, fludarabine and melphalan 1 6.7
Campath, fludarabine and treosulphan 1 6.7
Cyclophosphamide, rituximab and
busulfan
1 6.7
Melphalan, fludarabine and campath 1 6.7
Rabbit ATG, busulfan and cyclo-
phosphamide
1 6.7
Treosulfan and cyclophosphamide 1 6.7
Donor Match
HLA matching was defined as 10/10 match (excluding
HLA-DP), where HLA class I was largely low resolution and
HLA class II high resolution typed. Except for one HSCT
(9/10 match – HLA-A mismatched, unrelated donor) all were
10/10 HLA matched (Table 3).
TABLE 3: Donor Match
Donor Match Number of
Patients
% of Se-
ries
Unrelated donor (9/10 match) 1 6.7
Fully matched sibling donor 4 26.8
Fully matched unrelated donor 8 53.6
Fully matched maternal donor 1 6.7
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CMV Status
Ten patients tested negative for CMV both pre and post
BMT. Two patients tested negative for CMV pre-BMT and
positive for CMV post-BMT. Two patients tested positive for
CMV pre-BMT and negative for CMV post-BMT. Two pa-
tients had post-transplant adenovirus infection (Table 4).
TABLE 4: CMV Status
CMV Status Pre- and Post- BMT Number of
Patients
% of Se-
ries
Negative pre and post 10 67
Negative pre, positive post 2 13.3
Positive pre, negative post 2 13.3
Results
The mean age at diagnosis was 8.8 years (range 3.2-18.4
years). The mean number of days post-BMT until onset of
HC was 20.8 (range 1 – 51). While all patients tested urine
positive for BKV at the clinical onset of HC, only four pa-
tients had viral quantification, with viral loads ranging from
97,000 to >1 billion/ml. 8 patients had clinical HC (Table 5).
Ten patients experienced acute GVHD (grade I: 6 patients,
grade II: 3 patients, grade 4: 1 patient).
TABLE 5: Grade of Hemorrhagic Cystitis
Grade of HC No of patients
0 4 (BKV viruria only)
I 4
II 2
III 1
IV 3
Grade6 Grading System for HC
Grade I Microscopic haematuria
Grade II Marcoscopichaematuria
Grade III Macroscopic haematuria with small clots
Grade IV Gross haematuria with clots causing urinary tract
obstruction requiring instrumentation for clot evacua-
tion
Four patients received medical management for their HC.
Treatments included hyperhydration, MESNA, blood and
platelet transfusion, premarin and oxybutynin (Table 6).
Two patients received both medical and surgical manage-
ment which included cystoscopy with clot evacuation, blad-
der irrigation and supra-pubic catheter insertion. One pa-
tient received exclusive surgical management (Table 7).
Seven patients were treated conservatively.
TABLE 6: Medical Management
Management Strategy Number of
Patients
% of
Series
Conservative management 7 46.9
Hyperhydration 4 26.8
MESNA 3 20.1
Blood and/or platelet transfusion 2 13.3
Premarin and oxybutynin 1 6.7
Table 7: Surgical Management
Management Strategy Number of
Patients
% of
Series
Cystoscopy and clot evacuation 2 13.3
Heparinised saline bladder irrigation 2 13.3
Supra-pubic catheter insertion 1 6.7
Outcome
Of the fourteen patients two died.  One died from multi
organ failure, sepsis, on the basis of chronic granulomatous
disease, with BMT cited in part II of the death certificate.
The other patient died from pulmonary haemorrhage,
pneumonia, also with underlying chronic granulomatous
disease, with BMT cited in part II of the death certificate.
The remaining twelve children survived to discharge and in
all cases but one the HC was self-limiting. Eleven went home
symptom free and one continued to have occasional macro-
scopic haematuria on discharge (Table 8).
TABLE 8: Final patient outcome
Number of
Patients
% of
Series
Full recovery 11 73.7
Died 2 13.3
Occassional macroscopic haematuria 1 6.7
Discussion
Post-engraftment HC tends to present within one month of
neutrophil engraftment, resulting in variable disease severity
and duration (one week to four months)7 suggesting multiple
contributing risk factors. A three-phase model for
post-engraftment HC has been suggested: uroepithelial insult
by chemotherapy and radiation providing a permissive envi-
ronment for virus replication (phase 1), reactivation second-
ary to immunosuppression (phase 2), and attack of infected
uroepithelial cells by donor lymphoid cells upon engraft-
ment, resulting in tissue destruction (phase 3)8. HLA and
immune response gene polymorphisms are also likely to play
a role in viral immune responses, as has previously been
demonstrated in BK-virus nephropath.9, 10
BK-virus
BK-virus is a member of the Polyomaviridae family and was
first described in 1971. It was isolated in cell culture from
the urine of an asymptomatic immunosuppressed patient.11
Primary infection with BK-virus usually occurs in childhood
and is generally asymptomatic. Thereafter, the virus lies
latent in the host. BK-virus is urotheliotropic, affecting epi-
thelia of renal calyces, renal pelvis, ureter and urinary blad-
der. The widespread frequency of BK-virus in children sug-
gests common routes of transmission such as respiratory or
faecalspread.6 Post HSCT HC with BK-virus is widely be-
lieved to result from reactivation of latent virus, although
new or reinfection has also been postulated.9, 12-14 Urinary BK
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viral load can be quantified by PCR and urinary BK viral
load peaks have been found to correlate with subsequent
development of HC.8, 15-17 Urine BK viral loads of >9 x 106
copies/ml and blood BK viral load >1 x 103 copies/ml are
predictive of HC in children, with a higher sensitivity for
urine monitoring.6
Incidence of BK-virus associated HCis varied across different
transplant populations, ranging from 3.6% to 20%, according
to definition of HC used.  A number of prospective and
retrospective case series have investigated risk factors for the
development of post-engraftment HC, including
myeloablative conditioning,18 unrelated donor trans-
plants,19-21 and Adenovirus and CMV infection.22-25 Demo-
graphic risk factors include male sex,23, 26 and age >10 years
27-30. GvHD is a consistent risk factor in paediatric 26, 28, 31,
mixed 21, 30, 34, and adult 20 study cohorts. Busulphan 21, 34 and
cyclophosphamide28, 35 conditioning which are important risk
factors for pre-engraftment HC, seem also to increase risk of
post-engraftment HC. Immunosuppressive therapies, in-
cluding T-cell depletion, ATG, methotrexate, cyclosporin
and tacrolimus all lead to a higher incidence of HC.21, 28, 29,
36-38
The management of paediatric patients with post-HSCT HC
is difficult.  The clinician is confronted with a condition
that is potentially life threatening with significant associated
morbidity.  The recent toxic insult, profound immunosup-
pression and co-morbidities such as renal impairment se-
verely restrict therapeutic options, however, a recent sys-
tematic review supports MESNA and hyperhydration as
medical preventative measures and use of recombinant Fac-
tor VII in the emergency treatment of acute haemorrhage
unresponsive to alternative interventions.6
Medical Urological Management
Hyperhydration with forced diuresis has been studied in the
context of pre-engraftment HC caused by the toxic metabo-
lites of cyclophosphamide or ifosfamide.  The uroprotective
effect of 2-mercaptoethane sodium (MESNA) as a
uroprotective antitoxic agent has been investigated as part of
high-quality chemotherapy drug trials, and also with regards
to efficacy, tolerability and safety compared with
hyperhydration5, 39 or prophylactic bladder irrigation.40 Re-
sults are equivocal, with only one trial reporting an ad-
vantage of MESNA over forced diuresis/hyperhydration.4
MESNA and hyperhydration appear to be equally effective
in preventing HC, although current studies do not distin-
guish between early and late onset HC, therefore the protec-
tive impact on post-engraftment, BK-virus associated HC
cannot clearly be determined.6
Recombinant activated Factor VII (rFVII) has a haemostatic
effect leading to formation of thrombin and a haemostatic
plug. rFVII was investigated in a randomised, place-
bo-controlled clinical trial.41 This study enrolled 100 pa-
tients aged >12 years with bleeding complications between
days 2-180 post-HSCT, 26 of whom had HC. rFVII was given
in 3 different doses (40, 80 and 160 μg/kg) as seven single
administrations over a 36 hour period, and compared with
placebo. Overall, a reduction of the bleeding score at end-
point (38h after first administration) was observed for 80
μg/kg, but not for 160 μg/kg. Six thromboembolic events,
including two deaths, were attributed to the study medica-
tion. A different dose regimen was used in a prospective case
series on patients with HC after high-dose chemotherapy.42
Seven adult patients received initial doses of 80 μg/kg, fol-
lowed by two further administrations of 120 μg/kg at 3-hour
intervals if bleeding persisted. Four patients had a complete,
and a further two had partial short lasting responses alt-
hough bleeding recurred to baseline within hours. Two fur-
ther small case series report doses of 100 and 400 μg/kg 43 and
90 and 270 μg/kg 44 to be effective in HC. As a standard rFVII
dose of 90 μg/kg costs around £4000 in the UK, treatments
according to the above study protocols would cost between
£12,000 (for three doses) and £28,000 (for seven doses),45
thereby limiting its use to the most severe of cases.
The evidence for other medical interventions commonly
used, and considered ‘conventional’ – systemic cidofovir,
oestrogen, hyperbaric oxygen therapy, bladder instillation
with alum, formalin or prostaglandins – have been reported
to have a weak evidence base, are potentially highly toxic, or
both.6
Hyperhydration was employed for three of our patients
(21%) with grades II, III and IV HC. MESNA was used for
one patient (7%) with grade II HC, and blood and platelet
transfusion, premarin and oxybutynin was employed for
another patient who also required surgical intervention with
bladder irrigation.
Surgical Urological Management
Grade III or IV HC with blood clots often requires surgical
intervention. Catheterisation with cystoscopic clot extrac-
tion may become necessary, and consideration should be
given to continuous bladder irrigation with normal saline for
prevention of clots and bladder tamponade, if required.6
HC can occasionally present so severe that it not only fails to
respond to conservative measures, but also puts a patient’s
life at risk due to uncontrollable haemorrhage or renal fail-
ure secondary to complete urinary tract obstruction.  Cur-
rent case literature indicates cystectomy as the final step in
the management of severe medically refractory HC.46
Whether a radical or subtotal cystectomy should be per-
formed depends largely on the policy of the unit. Preserva-
tion of the bladder neck has been recommended in children
because severe HC is improved by cystotomy, temporary
urinary diversion and bladder packing.47 Currently, subtotal
cystectomy with urethra and bladder neck preservation,
allowing subsequent reconstructive continent urological
surgery is the preferred option although experience is lim-
ited.6
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Other surgical management options including use of fibrin
glue, selective embolization, and intravesical hydrostatic
pressure have been reported to have a weak evidence base or
are associated with unacceptable risks.6
Catheterisation and bladder irrigation was only required for
two patients (14%) in the current case series population and
clot extraction for one patient (7%), indicating that the study
unit is adhering to current guidelines in managing
post-HSCT HC conservatively where possible, reserving
invasive, surgical treatment options only in cases of grade IV
HC refractive to simple treatment options.
Conclusion
Current guidance on management of post-HSCT HC advo-
cates the following 6 :
 Prevention by addressing known risk factors early, em-
ploying the best possible donor-recipient matching, us-
ing the least toxic conditioning regimen with
MESNA/hyperhydration, tight monitoring of viral titres
and prompt treatment of re-activation in the pe-
ri-transplant period, GvHD prevention and tightly
monitored immunosuppression.
 Optimal supportive treatment of manifest HC, with a
conservative approach wherever possible and accom-
panying further management if required: ensuring ap-
propriate hydration and maintenance of renal function,
haematological homoeostasis (preserving high platelet
counts, appropriate red cell counts and levels of clotting
factors), pain relief, catheterisation with cystoscopic clot
extraction and continuous bladder irrigation with nor-
mal saline for prevention of clots and bladder
tamponade, if necessary.
 Early and close collaboration between medical and sur-
gical teams in the management of these patients to co-
ordinate and optimise timing of necessary interventions.
 As post-engraftment HC is by nature a transient condi-
tion that resolves with immune reconstitution, the goal
is for a conservative approach avoiding measures that
may inflict long-term consequences on the patient.
Given the low grades of recommendation, any further
interventions would have to be considered on an indi-
vidual basis for a given clinical scenario, carefully bal-
ancing benefits and risks.
There is limited available evidence for other potential thera-
peutic strategies highlighting the need for more research into
the pathophysiology of HSCT-associated HC. Commonly
used interventions with possible clinical benefit (e.g.
cidofovir, ciprofloxacin) still require to be evaluated in mul-
ti-centre, high-quality studies. Potential future preventative
and therapeutic options, such as modulation of conditioning,
immunosuppression and engraftment, new antiviral and
anti-inflammatory and less nephrotoxic agents need to be
assessed.6
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